Homeolab SA - Výsledky vyhľadávania

astrazeneca ab - olaparib - ovariálne nádory - antineoplastické činidlá - ovariálnych cancerlynparza je označené ako monotherapy pre:udržiavaciu liečbu dospelých pacientov s pokročilým (figo fázy iii a iv) brca1/2-zmutoval (germline a/alebo somatických) high-grade epitelové vaječníkov, fallopian trubice alebo primárne peritoneal rakovine, ktorí sú v reakcii (úplné alebo čiastočné) po ukončení prvej línie platinum-založené chemoterapia. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 a 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacienti by mali mať predtým liečení anthracycline a taxane v (neo)adjuvantnej alebo metastatickým nastavenie pokiaľ pacienti neboli vhodné pre tieto liečby (pozri časť 5. u pacientov s hormonálny receptor (hr)-pozitívnou rakovinou prsníka, by tiež mali mať postupoval alebo po pred žliaz s vnútornou sekréciou, terapie, alebo byť považované za nevhodné pre žliaz s vnútornou sekréciou, terapia. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.